Prescription drug recall for manufacturing quality control deviations
Northwind Pharmaceuticals is recalling 33 bottles of Doxazosin 4mg tablets due to manufacturing quality control deviations. No illnesses or injuries have been reported.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II with CGMP deviations represents a risk of harm with no reported illnesses or injuries, fitting the Score 3 (High) criterion for risk-of-harm products without reported injury.
Plain-English summary
Northwind Pharmaceuticals LLC is recalling 33 bottles of Doxazosin Tablets, USP 4mg (prescription only) because of Current Good Manufacturing Practice (CGMP) deviations. The affected product has lot number F107752201 and an expiration date of May 31, 2024. The product was distributed nationwide across the United States.
CGMP deviations indicate quality control and manufacturing practice concerns that could affect the safety and efficacy of the medication. Northwind Pharmaceuticals initiated this voluntary recall on March 16, 2023.
No illnesses or injuries have been reported in connection with this recall. Consumers who have received this medication should consult with their healthcare provider or pharmacist. Healthcare providers and pharmacists should identify and quarantine affected product and return it to the distributor.
The recalled product
- Product
- DOXAZOSIN (DOXAZOSIN)
- Brand
- DOXAZOSIN
- Manufacturer
- Northwind Pharmaceuticals LLC
- Category
- Drug — Prescription
- Hazard
- Affected units
- 33
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: F107752201
- Exp. Date 05/31/2024
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 7 recalled by Northwind Pharmaceuticals LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 7 products in this recall →Related recalls
Same brand · DOXAZOSIN
- ModeratePrescription Doxazosin Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- HighDoxazosin tablets recalled due to manufacturing quality control deviations
FDA (Drugs) · 2023-03-08
- ModerateAccord Healthcare Doxazosin Tablets Recalled for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModeratePrescription Doxazosin Tablets Recalled for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Northwind Pharmaceuticals LLC
See all →- ModerateDouble strength antibiotic bottles recalled over micro-organism on packaging coil
FDA (Drugs) · 2025-09-24
- ModerateDrug Recall: Buspirone Tablets Over Manufacturing Process Deviations
FDA (Drugs) · 2023-05-03
- ModerateFDA Recalls Glimepiride Tablets for Manufacturing Deviations
FDA (Drugs) · 2023-05-03
- ModerateAtorvastatin Calcium Tablets Recalled for Manufacturing Quality Violations
FDA (Drugs) · 2023-05-03
- ModerateTadalafil Tablets 20 mg recalled due to manufacturing deviations
FDA (Drugs) · 2023-05-03
Same hazard · manufacturing deviation
See all →- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
Similar recalls
- HighDoxazosin tablets recalled due to manufacturing quality control deviations
FDA (Drugs) · 2023-03-08
- ModerateDoxazosin Tablets Recalled Due to Manufacturing Process Deviations
FDA (Drugs) · 2023-04-12
- ModeratePrescription Doxazosin Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- ModeratePrescription Doxazosin Tablets Recalled for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModerateAccord Healthcare Doxazosin Tablets Recalled for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModerateDoxazosin Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-04-12